vs
Side-by-side financial comparison of First Bancorp, Inc (FNLC) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
First Bancorp, Inc is the larger business by last-quarter revenue ($25.8M vs $20.4M, roughly 1.3× Sight Sciences, Inc.). First Bancorp, Inc runs the higher net margin — 39.4% vs -20.4%, a 59.8% gap on every dollar of revenue. On growth, First Bancorp, Inc posted the faster year-over-year revenue change (17.5% vs 6.9%). First Bancorp, Inc produced more free cash flow last quarter ($34.6M vs $-2.0M). Over the past eight quarters, First Bancorp, Inc's revenue compounded faster (18.1% CAGR vs 2.9%).
Patriot Bank, N.A. (PNBK) is the bank holding company for Stamford, Connecticut-based Patriot Bank NA, and is traded on NASDAQ as PNBK.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
FNLC vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.8M | $20.4M |
| Net Profit | $10.2M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | 48.1% | -18.0% |
| Net Margin | 39.4% | -20.4% |
| Revenue YoY | 17.5% | 6.9% |
| Net Profit YoY | 39.7% | 64.9% |
| EPS (diluted) | $0.91 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.8M | $20.4M | ||
| Q3 25 | $24.5M | $19.9M | ||
| Q2 25 | $22.5M | $19.6M | ||
| Q1 25 | $21.8M | $17.5M | ||
| Q4 24 | $22.0M | $19.1M | ||
| Q3 24 | $20.5M | $20.2M | ||
| Q2 24 | $19.2M | $21.4M | ||
| Q1 24 | $18.5M | $19.3M |
| Q4 25 | $10.2M | $-4.2M | ||
| Q3 25 | $9.1M | $-8.2M | ||
| Q2 25 | $8.1M | $-11.9M | ||
| Q1 25 | $7.1M | $-14.2M | ||
| Q4 24 | $7.3M | $-11.8M | ||
| Q3 24 | $7.6M | $-11.1M | ||
| Q2 24 | $6.2M | $-12.3M | ||
| Q1 24 | $6.0M | $-16.3M |
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | 48.1% | -18.0% | ||
| Q3 25 | 45.2% | -39.7% | ||
| Q2 25 | 43.7% | -59.6% | ||
| Q1 25 | 39.3% | -79.2% | ||
| Q4 24 | 39.5% | -62.5% | ||
| Q3 24 | 44.6% | -55.7% | ||
| Q2 24 | 38.8% | -59.2% | ||
| Q1 24 | 39.3% | -76.4% |
| Q4 25 | 39.4% | -20.4% | ||
| Q3 25 | 37.0% | -41.0% | ||
| Q2 25 | 35.8% | -61.0% | ||
| Q1 25 | 32.5% | -80.8% | ||
| Q4 24 | 33.1% | -62.1% | ||
| Q3 24 | 36.9% | -54.9% | ||
| Q2 24 | 32.1% | -57.7% | ||
| Q1 24 | 32.5% | -84.4% |
| Q4 25 | $0.91 | $-0.07 | ||
| Q3 25 | $0.81 | $-0.16 | ||
| Q2 25 | $0.72 | $-0.23 | ||
| Q1 25 | $0.63 | $-0.28 | ||
| Q4 24 | $0.66 | $-0.23 | ||
| Q3 24 | $0.68 | $-0.22 | ||
| Q2 24 | $0.55 | $-0.25 | ||
| Q1 24 | $0.54 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $92.0M |
| Total DebtLower is stronger | $95.5M | $42.4M |
| Stockholders' EquityBook value | $283.1M | $63.9M |
| Total Assets | $3.2B | $115.3M |
| Debt / EquityLower = less leverage | 0.34× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $92.0M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $101.5M | ||
| Q1 25 | — | $108.8M | ||
| Q4 24 | — | $120.4M | ||
| Q3 24 | — | $118.6M | ||
| Q2 24 | — | $118.2M | ||
| Q1 24 | — | $127.3M |
| Q4 25 | $95.5M | $42.4M | ||
| Q3 25 | $95.5M | $42.4M | ||
| Q2 25 | $95.0M | $42.4M | ||
| Q1 25 | $70.0M | $42.4M | ||
| Q4 24 | $95.0M | $40.0M | ||
| Q3 24 | $95.0M | $37.1M | ||
| Q2 24 | $70.0M | $35.0M | ||
| Q1 24 | $70.0M | $35.0M |
| Q4 25 | $283.1M | $63.9M | ||
| Q3 25 | $274.6M | $64.3M | ||
| Q2 25 | $265.5M | $70.0M | ||
| Q1 25 | $259.7M | $77.6M | ||
| Q4 24 | $252.5M | $87.5M | ||
| Q3 24 | $256.8M | $95.0M | ||
| Q2 24 | $244.7M | $101.6M | ||
| Q1 24 | $242.6M | $109.2M |
| Q4 25 | $3.2B | $115.3M | ||
| Q3 25 | $3.2B | $116.3M | ||
| Q2 25 | $3.2B | $122.0M | ||
| Q1 25 | $3.2B | $129.7M | ||
| Q4 24 | $3.2B | $142.8M | ||
| Q3 24 | $3.1B | $143.6M | ||
| Q2 24 | $3.1B | $149.7M | ||
| Q1 24 | $3.0B | $155.6M |
| Q4 25 | 0.34× | 0.66× | ||
| Q3 25 | 0.35× | 0.66× | ||
| Q2 25 | 0.36× | 0.61× | ||
| Q1 25 | 0.27× | 0.55× | ||
| Q4 24 | 0.38× | 0.46× | ||
| Q3 24 | 0.37× | 0.39× | ||
| Q2 24 | 0.29× | 0.34× | ||
| Q1 24 | 0.29× | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $37.8M | $-1.8M |
| Free Cash FlowOCF − Capex | $34.6M | $-2.0M |
| FCF MarginFCF / Revenue | 133.9% | -9.7% |
| Capex IntensityCapex / Revenue | 12.5% | 0.8% |
| Cash ConversionOCF / Net Profit | 3.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $55.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $37.8M | $-1.8M | ||
| Q3 25 | $12.9M | $-8.7M | ||
| Q2 25 | $7.4M | $-7.5M | ||
| Q1 25 | $2.2M | $-11.6M | ||
| Q4 24 | $26.0M | $-3.5M | ||
| Q3 24 | $9.8M | $362.0K | ||
| Q2 24 | $6.4M | $-9.5M | ||
| Q1 24 | $-1.5M | $-9.8M |
| Q4 25 | $34.6M | $-2.0M | ||
| Q3 25 | $12.6M | $-8.9M | ||
| Q2 25 | $7.2M | $-7.8M | ||
| Q1 25 | $828.0K | — | ||
| Q4 24 | $24.6M | $-3.6M | ||
| Q3 24 | $9.6M | $311.0K | ||
| Q2 24 | $6.3M | $-9.5M | ||
| Q1 24 | $-1.8M | $-9.9M |
| Q4 25 | 133.9% | -9.7% | ||
| Q3 25 | 51.4% | -44.7% | ||
| Q2 25 | 32.1% | -39.6% | ||
| Q1 25 | 3.8% | — | ||
| Q4 24 | 111.7% | -18.9% | ||
| Q3 24 | 47.0% | 1.5% | ||
| Q2 24 | 32.9% | -44.7% | ||
| Q1 24 | -9.8% | -51.4% |
| Q4 25 | 12.5% | 0.8% | ||
| Q3 25 | 1.2% | 0.9% | ||
| Q2 25 | 0.6% | 1.1% | ||
| Q1 25 | 6.2% | 0.0% | ||
| Q4 24 | 6.7% | 0.7% | ||
| Q3 24 | 0.5% | 0.3% | ||
| Q2 24 | 0.3% | 0.4% | ||
| Q1 24 | 1.8% | 0.6% |
| Q4 25 | 3.72× | — | ||
| Q3 25 | 1.42× | — | ||
| Q2 25 | 0.91× | — | ||
| Q1 25 | 0.31× | — | ||
| Q4 24 | 3.58× | — | ||
| Q3 24 | 1.29× | — | ||
| Q2 24 | 1.03× | — | ||
| Q1 24 | -0.25× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FNLC
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
